U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H28N2O4.ClH
Molecular Weight 384.898
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROXATIDINE ACETATE HYDROCHLORIDE

SMILES

Cl.CC(=O)OCC(=O)NCCCOC1=CC(CN2CCCCC2)=CC=C1

InChI

InChIKey=FEWCTJHCXOHWNL-UHFFFAOYSA-N
InChI=1S/C19H28N2O4.ClH/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21;/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23);1H

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.drugsupdate.com/generic/view/456/Roxatidine | https://www.ncbi.nlm.nih.gov/pubmed/1717223 | https://www.ncbi.nlm.nih.gov/pubmed/20718616

Roxatidine is an histamine H2-receptor antagonist. Roxatidine is a potent and selective inhibitor of basal and stimulated gastric acid secretion through competitive blockade of H2-receptors. Total pepsin secretion is reduced in a dose-dependent manner. There is an independent mucosal protection action. Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome also it can be used as a premedication before anaesthesia. Roxatidine possessed a robust estrogenic activity.

CNS Activity

CNS Non-penetrant
1040
Curator's Comment: Small amounts of roxatidine were detectable in the CSF, the CSF to plasma ratio ranging from 0 to 0.89.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
Agonist
2752
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
Approved
8583
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
Approved
8583
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
Approved
8583
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
Approved
8583
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
157.5 ng/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
37.5 mg single, oral
dose: 37.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
329 ng/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
628.5 ng/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
353.6 ng/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=82
37.5 mg single, oral
dose: 37.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
530.2 ng/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=83
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1353.2 ng × h/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
37.5 mg single, oral
dose: 37.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2424.5 ng × h/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5275.2 ng × h/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2053.6 ng × h/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=82
37.5 mg single, oral
dose: 37.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
3587.5 ng × h/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=83
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.57 h
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
37.5 mg single, oral
dose: 37.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.03 h
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.01 h
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.62 h
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=82
37.5 mg single, oral
dose: 37.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
4.17 h
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=83
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
85%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2905248/
ROXATIDINE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/2906457/
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/2906457/
Other AEs: Skin rash...
Other AEs:
Skin rash (10%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2906457/
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2905241/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/2905241/
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (grade 3, 0.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2905241/
AEs

AEs

AESignificanceDosePopulation
Skin rash 10%
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/2906457/
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/2906457/
Rash grade 3, 0.5%
Disc. AE
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2905241/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/2905241/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP
303
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP
303
 no
PubMed

PubMed

TitleDatePubMed
Roxatidine attenuates mast cell-mediated allergic inflammation via inhibition of NF-κB and p38 MAPK activation.
2017-01-31
Roxatidine, an H(2) receptor blocker, is an estrogenic compound--experimental evidence.
2010-08
Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.
1991-08
Penetration of roxatidine into the cerebrospinal fluid.
1988
Histamine H2-receptor antagonistic action of N-(3-[3-(1-piperidinylmethyl)phenoxy]propyl)acetoxyacetamide hydrochloride (TZU-0460).
1985
Patents

Patents

JP2011157298
4
JPH06271467A
4

Sample Use Guides

In Vivo Use Guide
Peptic ulcer: 150 mg at bedtime or 75 mg bid daily for 4-6 weeks. Maintenance: 75 mg at bedtime. Gastro-oesophageal reflux disease: 75 mg bid or 150 mg at bedtime for 6-8 weeks. Gastritis: 75 mg once daily in the evening. Zollinger-Ellison syndrome: 75 mg bid. Premedication before anaesthesia: 75 mg in the evening on the day before surgery and repeated 2 hours before induction of anaesthesia. Alternatively, 150 mg once on the night before surgery. Intravenous Upper gastrointestinal haemorrhage: 75 mg bid via slow injection or infusion.
Route of Administration: Other
In Vitro Use Guide
6.25-25 uM Roxatidine suppressed the PMACI-induced production of pro-inflammatory cytokines in HMC-1
Name Type Language
ROXATIDINE ACETATE HYDROCHLORIDE
MART.   MI   USAN   WHO-DD  
USAN  
Official Name English
ALTAT
Preferred Name English
ROXATIDINE ACETATE HYDROCHLORIDE [MI]
Common Name English
PIFATIDINE HYDROCHLORIDE
Common Name English
ROXATIDINE ACETATE HYDROCHLORIDE [JAN]
Common Name English
ROXATIDINE ACETATE HCL
Common Name English
TZU-0460
Common Name English
HOE-760
Code English
ROXATIDINE ACETATE HYDROCHLORIDE [USAN]
Common Name English
ROXATIDINE ACETATE HYDROCHLORIDE [MART.]
Common Name English
HOE 760
Code English
N-(3-((.ALPHA.-PIPERIDINO-M-TOLYL)OXY)PROPYL)GLYCOLAMIDE ACETATE MONOHYDROCHLORIDE
Systematic Name English
NSC-760384
Code English
Roxatidine acetate hydrochloride [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29702
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
Code System Code Type Description
DRUG BANK
DBSALT000906
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
PRIMARY
NCI_THESAURUS
C152266
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
PRIMARY
SMS_ID
100000085398
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
PRIMARY
ChEMBL
CHEMBL46102
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
PRIMARY
FDA UNII
60426GOR1E
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
PRIMARY
CAS
93793-83-0
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
PRIMARY
PUBCHEM
56704
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
PRIMARY
NSC
760384
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
PRIMARY
RXCUI
236543
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
PRIMARY RxNorm
EVMPD
SUB04278MIG
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
PRIMARY
EPA CompTox
DTXSID2046670
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
PRIMARY
MERCK INDEX
m9677
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
PRIMARY Merck Index
USAN
AA-99
Created by admin on Mon Mar 31 18:53:17 GMT 2025 , Edited by admin on Mon Mar 31 18:53:17 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of ROXATIDINE
PARENT (SALT/SOLVATE)
Structure of ROXATIDINE ACETATE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966